Background. Systemic sclerosis (SSc) and localized scleroderma (LoS) are two different diseases that may share some features. We evaluated the relationship between SSc and LoS in our case series of SSc patients. Methods. We analysed the clinical records of 330 SSc patients, in order to find the eventual occurrence of both the two diseases. Results. Eight (2.4%) female patients presented both the two diagnoses in their clinical histories. Six developed LoS prior to SSc; in 4/6 cases, the presence of autoantibodies was observed before SSc diagnosis. Overall, the median time interval between LoS and SSc diagnosis was 18 (range 0–156) months. Conclusions. LoS and SSc are two distinct clinical entities that may coexist. Moreover, as anecdotally reported in pediatric populations, we suggested the possible development of SSc in adult patients with LoS, particularly in presence of Raynaud’s phenomenon or antinuclear antibodies before the SSc onset.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2BCkYMm
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Pulmonary complications post hematopoietic stem cell transplant in dyskeratosis congenita: analysis of oxidative stress in lung fibrobl...
-
Abstract Desmoplastic small round cell tumor (DSCRT) is a rare malignancy most often seen in the abdomen or pelvis of young men. Unfortuna...
-
Here is your sample essay on Advertising Advertising is an important element of our culture because it reflects and attempts to change our l...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2nGQ2DC via IFTTT
-
Objective To determine the association between neuroendocrine tumor (NET) biomarker levels and the extent of disease as assessed by 68 Ga DO...
-
Abstract Ankylosing spondylitis (AS) is characterized by excessive bone formation with syndesmophytes, leading to bony ankylosis. The cont...
-
by Mindaugas Paužuolis, Torsten Eich, Joachim Burman Background Natalizumab (NTZ) is a drug that has been widely used in the treatment of m...
-
Abstract Purpose To develop the first photoactive biomaterial coating capable of controlled drug dosing via inclusion of synthesised drug-...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου